Shots:

• The EMA has approved Bayer’s Eylea® (aflibercept) injection pre-filled syringe with the EC’s decision applies to all 27 EU member states as well as the UK- Iceland- Norway and Liechtenstein
• The P-IV ALTAIR study assessing Eylea (aflibercept) with T&E dosing regimens in patients with wet AMD- demonstrated a reduction in injection burden- i.e. up to 60% patients were able to achieve injection intervals of @3mos. (12wks. interval) or >40% achieved injection intervals of 4mos.(16wks. interval)
• Eylea is a VEGF inhibitor targeting VEGF-A and PLGF- formulated as an injection for the eye- act by blocking the growth of new blood vessels and by decreasing vascular permeability in the eye and is approved therapy for wet AMD- macular edema following RVO- DME and myopic CNV

Click here ­to­ read full press release/ article | Ref: Bayer | Image: Pinterest